

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. – 95. (Canceled)
96. (New) An isolated polypeptide selected from the group consisting of:
  - (a) a polypeptide comprising an amino acid sequence of SEQ ID NO: 5;
  - (b) a biologically active fragment of the polypeptide of (a); and
  - (c) an immunogenic fragment of the polypeptide of (a).
97. (New) An isolated polypeptide of claim 96 consisting of the polypeptide of (a).
98. (New) An isolated polypeptide of claim 96 consisting of a biologically active fragment of the polypeptide of (a).
99. (New) An isolated polypeptide of claim 96 consisting of an immunogenic fragment of the polypeptide of (a).
100. (New) An isolated polypeptide of claim 96 encoded by a polynucleotide selected from the group consisting of:
  - (i) a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 25;
  - (ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to SEQ ID NO: 25;
  - (iii) a polynucleotide comprising a portion of the polynucleotide sequence of SEQ ID NO: 53 that specifically identifies SEQ ID NO: 25.
  - (iv) a polynucleotide comprising a polynucleotide complementary to the polynucleotide of (i), (ii), or (iii);
  - (v) an RNA equivalent of the polynucleotide of (i), (ii), (iii) or (iv);
  - (vi) a polynucleotide of (i), (ii) or (iii) further comprising a promoter sequence operably linked to said polynucleotide of (i), (ii) or (iii).

101. (New) An isolated polypeptide of claim 96 produced recombinantly.
102. (New) An isolated polypeptide of claim 100 produced by culturing a cell transformed with a polynucleotide of (iv) under conditions suitable for expression of the polypeptide, and recovering the polypeptide so expressed.
103. (New) An isolated antibody that specifically binds to a polypeptide of claim 96.
104. (New) An isolated antibody of claim 103, wherein said antibody is selected from the group consisting of a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a single chain antibody, a Fab fragment, a F(ab')<sub>2</sub> fragment, and a humanized antibody.
105. (New) An isolated antibody of claim 103, wherein said antibody is selected by screening a recombinant immunoglobulin library.
106. (New) An isolated antibody of claim 103, wherein said antibody is selected by screening a Fab expression library.
107. (New) An isolated antibody that specifically binds to a polypeptide of claim 100.
108. (New) An isolated antibody of claim 107, wherein said antibody is selected from the group consisting of a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a single chain antibody, a Fab fragment, a F(ab')<sub>2</sub> fragment, and a humanized antibody.
109. (New) An isolated antibody of claim 107, wherein said antibody is selected by screening a recombinant immunoglobulin library.
110. (New) An isolated antibody of claim 107, wherein said antibody is selected by screening a Fab expression library.
111. (New) A method of detecting a polypeptide of interest in a sample, comprising:  
incubating the sample with an antibody that specifically binds to a polypeptide of claim 96 under conditions suitable for binding of the antibody to the polypeptide of interest if present in the sample; and  
detecting binding of the polypeptide of interest to the antibody, wherein binding indicates the presence or amount of the polypeptide of interest in the sample.

112. (New) A method of claim 111, wherein the sample is a body fluid sample from a human.
113. (New) An isolated polynucleotide selected from the group consisting of:
- (i) a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 25;
  - (ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to SEQ ID NO: 25;
  - (iii) a polynucleotide comprising a portion of the polynucleotide sequence of SEQ ID NO: 53 that specifically identifies SEQ ID NO: 25.
  - (iv) a polynucleotide comprising a polynucleotide complementary to the polynucleotide of (i), (ii), or (iii);
  - (v) an RNA equivalent of the polynucleotide of (i), (ii), (iii) or (iv);
  - (vi) a polynucleotide of (i), (ii) or (iii) further comprising a promoter sequence operably linked to said polynucleotide of (i), (ii) or (iii).